Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Bloedmonitor 2022: te weinig kennis over bloed en plasma doneren
aug 2022 | Benigne hematologie